BioSpace News Archive

Zucara Therapeutics Inc. today announced that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes (“T1D”).

A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today the release of a new peer-reviewed journal publication from a study conducted at Karolinska University Hospital (KUH), Solna, Stockholm, Sweden.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today announced that the European Commission (EC) this week authorized a variation for IMCIVREE® (setmelanotide) that allows for dosing in patients with POMC or LEPR deficiency who have mild, moderate or severe renal impairment.

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to report that in cohort six of a Phase I clinical trial, RECCE® 327 (R327) demonstrated a good safety and tolerability profile among 10 healthy male subjects intravenously dosed at 4,000mg (an 80-fold increase from cohort one at 50mg).

Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an α 7 β 1 integrin activating antibody for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD).

Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent).

PharmaEssentia Honored at the National Organization of Rare Disorders (NORD ® ) 2022 Rare Impact Awards for the Introduction of BESREMi ® (ropeginterferon alfa-2b-njft) for Polycythemia Vera.

VBI Vaccines Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM).